This link will take you to a non-ViiV Healthcare website. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third-parties.

  • Australia
  • Belgium
  • Canada (English)
  • Canada (Français)
  • Deutschland
  • España
  • France
  • Italia
  • Netherlands
  • Portugal
  • Switzerland
  • United Kingdom
  • United States
  • 日本
  • See more countries
ViiV Healthcare Exchange ViiV Healthcare Exchange ViiV Healthcare Exchange
  • REPORT AN ADVERSE EVENT
  • Healthcare Professionals
  • I am a patient
  • Public site
  • REPORT AN ADVERSE EVENT
  • Tivicay/Epivir▼ Prescribing Information
  • Juluca▼ Prescribing Information
  • HOME
  • HOME
  • OUR MEDICINES
  • RESOURCES
  • EXPERT EDITORIALS
  • PRESCRIBING INFORMATION
    • Tivicay (dolutegravir)
    • Epivir (lamivudine)
    • Juluca▼ (dolutegravir / rilpivirine)
    • Celsentri (maraviroc)
    • Kivexa (abacavir / lamivudine)
    • Triumeq (dolutegravir / abacavir / lamivudine)
    • Dovato (dolutegravir / lamivudine)
  • Search

Site Map

  • Welcome
    • Our Medicines
      • JULUCA
      • TRIUMEQ
        • Triumeq Prescribing Information
      • TIVICAY
        • Tivicay Prescribing Information
      • DTG+3TC
      • Two-drug, dolutegravir-based regimens 
    • Resources
      • Formulary packs
      • Videos
      • Publications
        • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials1

        • SWORD Studies
        • SAILING study (48-week data)
        • SINGLE study (144-week data)
      • Posters
      • Slide Sets
      • HIV Guidelines
    • Therapy Area
      • Grants & Donations
      • ISS
    • News & Events
      • News
        • CROI 2019 - TD/TND dolutegravir▼+ lamivudine
        • CROI 2019 - Lamidol
        • CROI 2019 - Dawning sub-analysis
        • Glasgow 2018—2-drug regimen
        • Glasgow 2018—Comparable viral decay
        • Glasgow 2018 Comparison of viral replication
        • Glasgow 2018 Comparison of viral replication
    • I am a patient
      • I am a Patient taking Juluca (dolutegravir/rilpivirine)
      • I am a patient taking Triumeq (dolutegravir/abacavir/lamivudine)
      • I am a patient taking Tivicay (dolutegravir)
      • I am a patient taking Celsentri (maraviroc)
      • I am a patient taking Kivexa (abacavir/lamivudine)
    • Contact a ViiV Healthcare Advisor
    • Report an Adverse Event
    • Privacy Policy
    • Terms and Conditions

© 2020 ViiV Healthcare group of companies or its licensor.
All rights reserved.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

ViiV Healthcare UK Limited
Registered in England
Company number: 06990358
Registered office:
980 Great West Road,
Brentford,
Middlesex,
TW8 9GS

  • Privacy Policy
  • Terms and Conditions
  • Contact us

PM-GB-HVX-WCNT-200003 | March 2020

Back to top